Atrial Fibrillation (Prevention of Stroke)
5
3
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
The Southern-Norway Post-Stroke Atrial Fibrillation Study
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Responding to AF: Pill-in-Pocket Anticoagulation Guided by Automated Monitoring and Alerts
Registry Initiative Across Borders for Atrial Fibrillation in Africa
Real-Life Evidence on Stroke Prevention in SPAF